Antifúngicos de uso sistémico

IF 1.5 4区生物学 Q4 MYCOLOGY

Revista Iberoamericana De Micologia Pub Date : 2021-04-01 DOI:10.1016/j.riam.2021.04.004

Inmaculada Quiles-Melero, Julio García-Rodríguez

{"title":"Antifúngicos de uso sistémico","authors":"Inmaculada Quiles-Melero, Julio García-Rodríguez","doi":"10.1016/j.riam.2021.04.004","DOIUrl":null,"url":null,"abstract":"<div><p>Las infecciones fúngicas invasivas han aumentado en las últimas décadas y las opciones terapéuticas para combatirlas son limitadas. Los agentes antifúngicos empleados son útiles y tienen óptima actividad <em>in vitro</em>, pero pierden eficacia debido al desarrollo de resistencias por parte de los hongos. El incremento de especies con resistencia primaria o secundaria a algunos fármacos antifúngicos ha generado la necesidad de desarrollar nuevas formulaciones o recurrir a alternativas como la combinación de fármacos. En este artículo se revisará el espectro de actividad de las principales familias de antifúngicos, polienos, azoles, equinocandinas, 5-fluorocitosina y nuevos fármacos antifúngicos, así como los mecanismos de resistencia descritos contra los mismos.</p></div><div><p>Invasive fungal infections have increased over the last decades and the therapeutic choices to treat them are limited. The antifungal agents currently available are useful and have optimal in vitro activity; however, their activity can be lowered due to the development of fungal resistance. The increase in primary or secondary resistance to some antifungal drugs has led to the search of alternatives such as the combination of drugs or the development of new antifungals. In this paper, the activity of the main families of antifungal drugs, polyenes, azoles, echinocandins, 5-fluorocytosine and other new antifungal drugs, are reviewed. The main resistance mechanisms developed by fungi are also described.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":"38 2","pages":"Pages 42-46"},"PeriodicalIF":1.5000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.04.004","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Iberoamericana De Micologia","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130140621000309","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Las infecciones fúngicas invasivas han aumentado en las últimas décadas y las opciones terapéuticas para combatirlas son limitadas. Los agentes antifúngicos empleados son útiles y tienen óptima actividad in vitro, pero pierden eficacia debido al desarrollo de resistencias por parte de los hongos. El incremento de especies con resistencia primaria o secundaria a algunos fármacos antifúngicos ha generado la necesidad de desarrollar nuevas formulaciones o recurrir a alternativas como la combinación de fármacos. En este artículo se revisará el espectro de actividad de las principales familias de antifúngicos, polienos, azoles, equinocandinas, 5-fluorocitosina y nuevos fármacos antifúngicos, así como los mecanismos de resistencia descritos contra los mismos.

Invasive fungal infections have increased over the last decades and the therapeutic choices to treat them are limited. The antifungal agents currently available are useful and have optimal in vitro activity; however, their activity can be lowered due to the development of fungal resistance. The increase in primary or secondary resistance to some antifungal drugs has led to the search of alternatives such as the combination of drugs or the development of new antifungals. In this paper, the activity of the main families of antifungal drugs, polyenes, azoles, echinocandins, 5-fluorocytosine and other new antifungal drugs, are reviewed. The main resistance mechanisms developed by fungi are also described.

查看原文本刊更多论文

全身使用的抗真菌药物

在过去的几十年里，侵袭性真菌感染有所增加，对抗它们的治疗选择有限。所使用的抗真菌药物是有用的，在体外具有最佳的活性，但由于真菌产生耐药性而失去效力。对一些抗真菌药物具有一级或二级耐药性的物种的增加产生了开发新配方或使用替代药物(如联合药物)的需求。本研究的目的是评估抗真菌药物的抗真菌活性，并确定抗真菌药物的抗真菌活性，以及抗真菌药物的耐药性机制。侵袭性真菌感染在过去几十年中有所增加，治疗它们的治疗选择有限。目前可用的抗真菌药物是有用的，具有最佳的体外活性;然而，由于真菌抗性的发展，它们的活动可能会减少。= =地理= =根据美国人口普查，这个县的面积为，其中土地和(1.1%)水。本文回顾了主要的抗真菌药物家族，如多烯类、唑类、棘球绦虫类、5-氟催产素和其他新型抗真菌药物的活性。= =地理= =根据美国人口普查，这个县的面积为。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Iberoamericana De Micologia MYCOLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

81 days

期刊介绍： Revista Iberoamericana de Micología (Ibero-American Journal of Mycology) is the official journal of the Asociación Española de Micología, Asociación Venezolana de Micología and Asociación Argentina de Micología (The Spanish, Venezuelan, and Argentinian Mycology Associations). The Journal gives priority to publishing articles on studies associated with fungi and their pathogenic action on humans and animals, as well as any scientific studies on any aspect of mycology. The Journal also publishes, in Spanish and in English, original articles, reviews, mycology forums, editorials, special articles, notes, and letters to the editor, that have previously gone through a scientific peer review process.